Get started
Author

Katja Mohorčič

Observed names: K. Mohorcic, Katja Mohorcic, Mohorcic Katja, Mohorcic, K., Mohorcic, Katja, Mohorčič, Katja
ORCID: 0009-0008-0838-0454
Observed ORCID: 0009-0008-0838-0454
OpenAlex ID: A5041297657
Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer
2024 · Vincent D. de Jager, Wim Timens, et al. · The Lancet Regional Health - Europe · 57
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries
2024 · Vincent D. de Jager, Wim Timens, et al. · The Lancet Regional Health - Europe · 53
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
2020 · Solange Peters, Sarah Danson, et al. · Journal of Thoracic Oncology · 53
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program
2021 · Oliver Illini, Maximilian Johannes Hochmair, et al. · Therapeutic Advances in Medical Oncology · 45
PDF
Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup
2020 · Christine Pirker, Agnes Bilecz, et al. · Clinical Cancer Research · 44
Expansion of Pulmonary CD8+CD56+ Natural Killer T-Cells in Hypersensitivity Pneumonitis
2007 · Peter Korosec, Katarina Osolnik, et al. · CHEST Journal · 43
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program
2022 · Oliver Illini, Hannah Fabikan, et al. · Therapeutic Advances in Medical Oncology · 31
PDF
Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study
2021 · Luka Brcic, Thomas Klikovits, et al. · Translational Lung Cancer Research · 31
PDF
Expression of FGFR1–4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity
2019 · Gregor Vlacic, Mir A. Hoda, et al. · Cells · 17
PDF
Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA)
2024 · Francesco Passiglia, Angela Listì, et al. · Journal of Thoracic Oncology · 14
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
2024 · Oliver Illini, Felix Carl Saalfeld, et al. · International Journal of Molecular Sciences · 12
PDF
Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis
2023 · Lidija Ljubicic, Urska Janzic, et al. · Radiology and Oncology · 7
PDF
Benefit of Consolidation Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer Patients Treated with Immunotherapy: Data from Slovenian Cohort
2025 · Marina Čakš, Urška Janžič, et al. · International Journal of Molecular Sciences · 6
PDF
Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination
2022 · Urska Janzic, Urska Bidovec-Stojkovic, et al. · Future Oncology · 6
A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers
2023 · Urska Janzic, Urska Bidovec-Stojkovic, et al. · Vaccines · 3
PDF
Immunophenotypes of anti-SARS-CoV-2 responses associated with fatal COVID-19
2022 · Julij Šelb, Barbara Bitežnik, et al. · ERJ Open Research · 3
PDF
154P CNS response to osimertinib in patients with EGFR mutated lung adenocarcinoma: Real world data
2018 · R. Devjak, N. Turnsek Hitij, et al. · Journal of Thoracic Oncology · 3
PDF
Beyond EML4: efficacy of targeted therapy in lung cancer patients with rare ALK fusions – a real-world retrospective analysis
2026 · Marie-Elisabeth Leßmann, Felix Carl Saalfeld, et al. · npj Precision Oncology · 1
PDF
EP08.02-122 Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP)
2022 · O. Illini, H. Fabikan, et al. · Journal of Thoracic Oncology · 1
Vardetector: a pure Python package to detect DNA called mutations in aligned RNA reads
2026 · Julij Šelb, Luka Dejanović, et al. · Scientific Reports
PDF
1782 Upfront palliative radiotherapy prior to chemoimmunotherapy in metastatic non-small lung cancer - a prospective, phase II study PRIMM (NCT 05440916)
2026 · Tanja Žnidarič Rakar, Marina Čakš, et al. · Radiotherapy and Oncology
2051eP The frequency of driver mutations in non-small cell lung cancer patients: Slovenian nationwide observational cohort trial
2025 · K. Mohorcic, R. Lustrik, et al. · Annals of Oncology
Rare ALK: Clinical characteristics and efficacy of targeted therapy in NSCLC with ALK fusions other than EML4::ALK.
2025 · Felix Carl Saalfeld, Marie-Elisabeth Leßmann, et al. · Journal of Clinical Oncology
P2.16A.01 Actionable Alterations Identification in NSCLC by Comprehensive Genomic Profiling for Clinical Trial Enrollment: EPROPA
2024 · S. Vallone, F. Passiglia, et al. · Journal of Thoracic Oncology
203 (PB191): Molecular biomarker testing in Slovenian non-small cell lung cancer patients in early and late stages of the disease
2024 · K. Mohorcic, R. Luštrik, et al. · European Journal of Cancer
Works count: 67
Citation count: 434
H-index: 11
I10-index: 11
Year
Topic
Type